Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Novavax, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Xenon Pharmaceuticals Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Novavax's SG&A expenses surged by over 2,250%, peaking in 2022 with a staggering $489 million. This reflects their aggressive expansion and increased operational activities, especially during the COVID-19 pandemic. In contrast, Xenon Pharmaceuticals maintained a more conservative growth, with expenses increasing by approximately 747%, reaching $46 million in 2023. This steady rise indicates a strategic focus on sustainable growth. The data highlights the contrasting strategies of these two companies, with Novavax opting for rapid expansion and Xenon prioritizing steady development. Understanding these trends provides valuable insights into the financial strategies of biotech firms.